查詢結果分析
相關文獻
- An Economic Evaluation on the Pharmaceutical Expenditure of Antihypertensive Agents in Taiwan from 1997 to 2002
- Impact of Introduction of Angiotensin Ⅱ Antagonist on the Antihypertensive Utilization in Taiwan
- 新治療類別降血壓藥物--血管張力素Ⅱ接受器阻斷劑
- 新一類降血壓藥物:血管收縮素接受體之拮抗劑
- 藥物經濟學之原則與方法在醫院藥局中的應用
- 作用於腎素血管收縮素系統(Renin-angiotensin System, RAS)之降壓藥物現況與未來展望
- 概述降高血壓藥物的分類與使用
- 高血壓藥物治療之現況
- 藥物經濟學(3):急性梗塞腦中風溶栓治療的成本效果分析
- 藥物經濟學(5):巴金森氏病內科治療的評估
頁籤選單縮合
題名 | An Economic Evaluation on the Pharmaceutical Expenditure of Antihypertensive Agents in Taiwan from 1997 to 2002=臺灣降血壓藥物耗用型態及其經濟分析 |
---|---|
作者 | 林銅祿; 高雅慧; 湯澡薰; 吳惠美; 鄭慧文; Lin, Tong-lu; Kao, Yang Yea-huei; Tang, Chao-hsiun; Wu, Huei-mei; Cheng, Hui-wen; |
期刊 | 藥物食品分析 |
出版日期 | 20070900 |
卷期 | 15:3 2007.09[民96.09] |
頁次 | 頁233-241+333 |
分類號 | 418.05 |
語文 | eng |
關鍵詞 | 藥物經濟; 藥品耗用; 降血壓藥物; 藥品日劑當量; Antihypertensive Agent; Defined daily dose; DDD; Drug utilization; Pharmaceutical expenditure; Pharmacoeconomics; |
中文摘要 | 本研究以全民健保1997~2002六年的門診申報檔案為範圍,分析不同類別降血壓藥物的耗用趨勢以及價量參數的變異。藥費變異的分析不同類別降血壓藥物的耗用趨勢以及價量參數的變異。藥費變異的分析係以下列五項參數予以解釋:相對藥品價格、病人數、平均就診次數、每次就診藥品日劑當量數及餘數。六年期間,降血壓藥物的費用成長了102%,主要來自於病人數及每次就診藥品日劑量數的增加,分別為34%及33%。其他的因素會由餘數的變異中呈現,餘數效應僅為7%。若再進一步探討其他的因素,可以發現原開發廠藥品有11%的成長,而學名藥品為12%。另一方面,醫院部分可以觀察到11%的成長,相反地,基層診所卻呈現11%的減少。此一變異或許顯示醫院中的醫師處方較多屬創新性的藥品,而基層診所的醫師則使用較多不具專利的學名藥品。 |
英文摘要 | Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1887 to 2002. The claims data were obtained from National Health Insurance Research Database (NHIRD), which include ambulatory service record and prescription data were of the entire population. Drug expenditure was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102% during this period, mainly due to the compounding effect from the increment of patients treated (34%) and DDD per physician visit (33%). The aggregate residual for antihypertensive agents only exerts a 7% effect. Detailed residual analysis revealed that the brand-name product did have 11% increment, while the generic product had a 12% decrement. It also showed that hospital sector had a positive 11% residual, while primary care clinics had an 11% decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the hospital sector adopted more new innovative medications, their counterparts at the primary care clinics tended to switch some off-patent products to the generics. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。